Literature DB >> 30814364

Huntingtin Aggregates and Mitochondrial Pathology in Skeletal Muscle but not Heart of Late-Stage R6/2 Mice.

Kerstin Kojer1, Tanja Hering1, Chantal Bazenet2, Andreas Weiss2, Frank Herrmann2, Jan-Willem Taanman3, Michael Orth1.   

Abstract

BACKGROUND: Cell or tissue specific background may influence the consequences of expressing the Huntington's disease (HD) mutation. Aggregate formation is known to occur in skeletal muscle, but not heart of the R6/2 fragment HD model.
OBJECTIVE: We asked whether aggregate formation and the expression and subcellular localization of huntingtin species was associated with mitochondrial dysfunction.
METHODS: We analyzed levels of soluble HTT and HTT aggregates, as well as important fission and fusion proteins and mitochondrial respiratory chain activities, in quadriceps and heart of the R6/2 N-terminal fragment mouse model (12 weeks, 160±10 CAG repeats).
RESULTS: Soluble mutant HTT was present in both tissues with expression higher in cytoplasmic/mitochondrial than nuclear fractions. HTT aggregates were only detectable in R6/2 quadriceps, in association with increased levels of the pro-fission factor DRP1 and its phosphorylated active form, and decreased levels of the pro-fusion factor MFN2. In addition, respiratory chain complex activities were decreased. In heart that was without detectable HTT aggregates, we found no evidence for mitochondrial dysfunction.
CONCLUSION: Tissue specific factors may exist that protect the R6/2 heart from HTT aggregate formation and mitochondrial pathology.

Entities:  

Keywords:  Huntingtin; fission and fusion; mitochondria; respiratory chain; skeletal muscle

Mesh:

Substances:

Year:  2019        PMID: 30814364     DOI: 10.3233/JHD-180324

Source DB:  PubMed          Journal:  J Huntingtons Dis        ISSN: 1879-6397


  9 in total

1.  Progressive cardiac arrhythmias and ECG abnormalities in the Huntington's disease BACHD mouse model.

Authors:  Yujie Zhu; Isaac Shamblin; Efrain Rodriguez; Grace E Salzer; Lita Araysi; Katherine A Margolies; Ganesh V Halade; Silvio H Litovsky; Steven Pogwizd; Michelle Gray; Sabine Huke
Journal:  Hum Mol Genet       Date:  2020-02-01       Impact factor: 6.150

Review 2.  Skeletal Muscle Pathogenesis in Polyglutamine Diseases.

Authors:  Caterina Marchioretti; Emanuela Zuccaro; Udai Bhan Pandey; Jessica Rosati; Manuela Basso; Maria Pennuto
Journal:  Cells       Date:  2022-07-03       Impact factor: 7.666

Review 3.  Molecular Pathophysiological Mechanisms in Huntington's Disease.

Authors:  Anamaria Jurcau
Journal:  Biomedicines       Date:  2022-06-17

Review 4.  Cell-Autonomous and Non-cell-Autonomous Pathogenic Mechanisms in Huntington's Disease: Insights from In Vitro and In Vivo Models.

Authors:  Jordi Creus-Muncunill; Michelle E Ehrlich
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

Review 5.  Molecular Mechanisms Underlying Muscle Wasting in Huntington's Disease.

Authors:  Manuela Bozzi; Francesca Sciandra
Journal:  Int J Mol Sci       Date:  2020-11-05       Impact factor: 5.923

Review 6.  Non-Cell Autonomous and Epigenetic Mechanisms of Huntington's Disease.

Authors:  Chaebin Kim; Ali Yousefian-Jazi; Seung-Hye Choi; Inyoung Chang; Junghee Lee; Hoon Ryu
Journal:  Int J Mol Sci       Date:  2021-11-19       Impact factor: 5.923

7.  Rosiglitazone Ameliorates Cardiac and Skeletal Muscle Dysfunction by Correction of Energetics in Huntington's Disease.

Authors:  Marta Tomczyk; Alicja Braczko; Paulina Mierzejewska; Magdalena Podlacha; Oliwia Krol; Patrycja Jablonska; Agata Jedrzejewska; Karolina Pierzynowska; Grzegorz Wegrzyn; Ewa M Slominska; Ryszard T Smolenski
Journal:  Cells       Date:  2022-08-27       Impact factor: 7.666

Review 8.  Therapeutic Strategies in Huntington's Disease: From Genetic Defect to Gene Therapy.

Authors:  Anamaria Jurcau; Maria Carolina Jurcau
Journal:  Biomedicines       Date:  2022-08-05

Review 9.  Purine Nucleotides Metabolism and Signaling in Huntington's Disease: Search for a Target for Novel Therapies.

Authors:  Marta Tomczyk; Talita Glaser; Ewa M Slominska; Henning Ulrich; Ryszard T Smolenski
Journal:  Int J Mol Sci       Date:  2021-06-18       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.